This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, L. Articles by Chang, E. H. Search for Related Content PubMed PubMed Citation Articles by Xu, L. Articles by Chang, E. H.

Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007

An ideal therapeutic for cancer would be one that selectively targets to tumor cells, is nontoxic to normal cells, and that could be systemically delivered, thereby reaching metastases as well as primary tumor. Immunoliposomes directed by monoclonal antibody or its fragments are promising vehicles for tumor-targeted drug delivery. However, there is currently very limited data on gene delivery using these vehicles. We have recently described a cationic immunoliposome system directed by a lipid-tagged, single-chain antibody Fv fragment (scFv) against the human transferrin receptor (TfR) that shows promising efficacy for systemic p53 tumor suppressor gene therapy in a human breast cancer metastasis model. However, the extremely low yield of this lipid-tagged scFv limited further downstream development and studies. Here we report a different expression strategy for the anti-TfR scFv, which produces high levels of protein without any tags, and a different approach for complexing the targeting scFv to the liposomes. This approach entails covalently conjugating the scFv to the liposome via a cysteine at the 3'-end of the protein and a maleimide group on the liposome. Our results show that this conjugation does not impair the immunological activity or targeting ability of the scFv. The scFv-cys targets the cationic liposome-DNA complex (lipoplex) to tumor cells and enhances the transfection efficiencies both in vitro and in vivo in a variety of human tumor models. This scFv-immunoliposome can deliver the complexed gene systemically to tumors in vivo, where it is efficiently expressed. In comparison with the whole antibody or transferrin molecule itself, the scFv has a much smaller size for better penetration into solid tumors. It is also a recombinant protein rather than a blood product; thus, large scale production and strict quality control are feasible. This new approach provides a promising system for tumor-targeted gene delivery that may have potential for systemic gene therapy of various human cancers.

This article has been cited by other articles:

				K. F. Pirollo, A. Rait, Q. Zhou, X.-q. Zhang, J. Zhou, C.-S. Kim, W. F. Benedict, and E. H. Chang Tumor-Targeting Nanocomplex Delivery of Novel Tumor Suppressor RB94 Chemosensitizes Bladder Carcinoma Cells In vitro and In vivo Clin. Cancer Res., April 1, 2008; 14(7): 2190 - 2198. [Abstract] [Full Text] [PDF]

				S. H. Hwang, A. Rait, K. F. Pirollo, Q. Zhou, V. M. Yenugonda, G. M. Chinigo, M. L. Brown, and E. H. Chang Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue Mol. Cancer Ther., March 1, 2008; 7(3): 559 - 568. [Abstract] [Full Text] [PDF]

				T. R. Daniels, P. P. Ng, T. Delgado, M. R. Lynch, G. Schiller, G. Helguera, and M. L. Penichet Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells Mol. Cancer Ther., November 1, 2007; 6(11): 2995 - 3008. [Abstract] [Full Text] [PDF]

				F. Liu, C. C. Conwell, X. Yuan, L. M. Shollenberger, and L. Huang Novel Nonviral Vectors Target Cellular Signaling Pathways: Regulated Gene Expression and Reduced Toxicity J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 777 - 783. [Abstract] [Full Text] [PDF]

				K. F. Pirollo, A. Rait, Q. Zhou, S. H. Hwang, J. A. Dagata, G. Zon, R. I. Hogrefe, G. Palchik, and E. H. Chang Materializing the Potential of Small Interfering RNA via a Tumor-Targeting Nanodelivery System Cancer Res., April 1, 2007; 67(7): 2938 - 2943. [Abstract] [Full Text] [PDF]

				L. Xu, D. Yang, S. Wang, W. Tang, M. Liu, M. Davis, J. Chen, J. M. Rae, T. Lawrence, and M. E. Lippman (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer Mol. Cancer Ther., February 1, 2005; 4(2): 197 - 205. [Abstract] [Full Text] [PDF]

				T. Khudairi and B.-A. Khaw Preservation of ischemic myocardial function and integrity with targeted cytoskeleton-specific immunoliposomes J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1683 - 1689. [Abstract] [Full Text] [PDF]

				W. Yu, K. F. Pirollo, B. Yu, A. Rait, L. Xiang, W. Huang, Q. Zhou, G. Ertem, and E. H. Chang Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide Nucleic Acids Res., March 16, 2004; 32(5): e48 - e48. [Abstract] [Full Text] [PDF]